Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the efficacy of the treatment using implantable
cardioverter defibrillator (ICD) implantation to that of the treatment using amiodarone in
the primary prevention of all-cause mortality in high-risk patients with Chagas
cardiomyopathy and non-sustained ventricular tachycardia (NSVT).
Phase:
N/A
Details
Lead Sponsor:
InCor Heart Institute
Collaborators:
Abbott Medical Devices Fundação de Amparo à Pesquisa do Estado de São Paulo Ministry of Health, Brazil St. Jude Medical